1450 results about "Type ii diabetes" patented technology

Provided are thiadiazolidine compounds of formula I

wherein R₁ is an organic group having at least 8 atoms selected from C or O, which is not linked directly to the N through a —C(O)— and comprising at least an aromatic ring, and their pharmaceutical compositions. These compounds are selective GSK-3 inhibitors and have improved bioavailability. They are useful for the treatment of GSK-3 mediated diseases, among others Alzheimer's disease, type II diabetes, depression and brain injury.

The invention relates to a medical apparatus including a device used in the treatment of weight loss, obesity and potentially other associated health problems, e.g., type II diabetes. The device is used to impede absorption of nutrients within the gastrointestinal tract, i.e., bypassing a portion of the gastrointestinal tract. The medical apparatus enables implantation of the device using minimally invasive techniques, such a transesophageal approach under visualization. The device may be implanted via a working channel of a medical scope, e.g., an endoscope or in combination with a medical scope.

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

The invention relates to a medical apparatus including a device used in the treatment of weight loss, obesity and potentially other associated health problems, e.g., type II diabetes. The device is used to impede absorption of nutrients within the gastrointestinal tract, i.e., bypassing a portion of the gastrointestinal tract. The medical apparatus enables implantation of the device using minimally invasive techniques, such a transesophageal approach under visualization. The device may be implanted via a working channel of a medical scope, e.g., an endoscope or in combination with a medical scope.

This invention relates to a method for prevention and treatment of Atherosclerosis, Peripheral Vascular Disease, Coronary Artery Disease, and age-related disorders including Osteoporosis, Arthritis, Type II Diabetes, Dementia and Alzheimer's disease in a subject comprising administering to said subject a therapeutically effective dosage of each component or combination of statins, bisphosphonates, cholesterol lowering agents or techniques, interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof, administered separately, in sequence or simultaneously. Inhibition of the signal transduction pathway for Interleukin 6 mediated inflammation is key to the prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, aging and age-related disorders including osteoporosis, type 2 diabetes, dementia and some forms of arthritis and tumors. Inhibition of Interleukin 6 mediated inflammation may be achieved indirectly through regulation of endogenous cholesterol synthesis and isoprenoid depletion or by direct inhibition of the signal transduction pathway including interleukin-6 inhibitor/antibody, interleukin-6 receptor inhibitor/antibody, gp130 protein inhibitor/antibody, tyrosine kinases inhibitors/antibodies, STAT transcription factors inhibitors/antibodies, altered IL-6, partial peptides of IL-6 or IL-6 receptor, or SOCS (suppressors of cytokine signaling) protein, or a functional fragment thereof. Said method for prevention and treatment of said disorders is based on inhibition of Interleukin-6 inflammation through regulation of cholesterol metabolism, isoprenoid depletion and inhibition of the signal transduction pathway.

The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

Provided herein are compounds of the formula (I):

as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

The present invention provides methods of administering an insulinotropic peptide in an amount effective to treat a disorder or condition while reducing nausea side effect by administering to a subject in need thereof an insulinotropic peptide conjugated to albumin. The present invention also provides methods of selecting a subject for administration of a conjugated insulinotropic peptide. Exemplary disorders or conditions treatable with an insulinotropic peptide include obesity and type II diabetes.

The present invention relates to a series of prodrugs of inhibitors of DP-IV with improved properties. The compounds can be used for the treatment of a number of human diseases, including impaired glucose tolerance and type II diabetes. The compounds of the invention are described by general formula (1); wherein R¹ is H or CN; R² is selected from CH₂R⁵, CH₂CH₂R⁵ and C(R³)(R⁴)—X²—(CH₂)_aR⁵; R³ and R⁴ are each independently selected from H and Me; R⁵ is selected from CON(R⁶)(R⁷), N(R⁸)C(=0)R⁹, N(R⁸)C(═S)R⁹, N(R⁸)SO₂R¹⁰ and N(R⁸)R¹⁰; R⁶ and R⁷ are each independently R¹¹(CH₂)_b or together they are —(CH₂)₂-Z-(CH₂)₂— or CH₂-o-C₆H₄-Z-CH₂—; R⁸ is H or Me; R⁹ is selected from R¹¹(CH₂)_b, R¹¹(CH₂)_bO and N(R⁶)(R⁷); R¹⁰ is R¹¹(CH₂)_b; R¹¹ is selected from H, alkyl, optionally substituted aryl, optionally substituted aroyl, optionally substituted arylsulphonyl and optionally substituted heteroaryl; R¹² is selected from H₂NCH(R¹³)CO, H₂NCH(R¹⁴)CONHCH(R¹⁵)CO, C(R¹⁶)═C(R¹⁷)COR¹⁸ and R¹⁹OCO; R¹³, R¹⁴ and R¹⁵ are selected from the side chains of the proteinaceous amino acids; R¹⁶ is selected from H, lower alkyl (C₁-C₆) and phenyl; R¹⁷ is selected from H and lower alkyl (C₁-C₆); R¹⁸ is selected from H, lower alkyl (C₁-C₆), OH, O-(lower alkyl (C₁-C₆)) and phenyl; R₁₉ is selected from lower alkyl (C₁-C₆), optionally substituted phenyl and R²⁰C(=0)OC(R²¹)(R²²); R²⁰, R²¹ and R²² are each independently selected from H and lower alkyl (C₁-C₆); Z is selected from a covalent bond, —(CH₂)_c—, —O—, —SO_d— and —N(R¹⁰)—; X¹ is S or CH₂; X² is O, S or CH₂; a is 1, 2 or 3; b is 0-3; c is 1 or 2; and d is 0, 1 or 2.

Provided herein are compounds of the formula (I):

as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of metabolic diseases and disorders such as, for example, type II diabetes mellitus.

The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.

The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.

The present invention relates to compounds of the general Formula (I),

• wherein R¹, R² and R³ are as defined in the description; to pharmaceutical compositions comprising these compounds; and to the use of the compounds for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes, and/or CNS disorders.

The present invention provides systems and methods for treating and controlling obesity and/or type II diabetes. In one aspect of the invention, a device comprises a hollow sleeve sized and shaped for positioning within a duodenum of the patient, an anchor coupled to the proximal end of the sleeve and being sized and shaped to inhibit distal migration of the sleeve and a plurality of elastomeric objects coupled to the distal end of the sleeve and being sized and shaped to inhibit proximal migration of the sleeve through a pylorus of the patient. The bypass device can be placed and removed endoscopically through the patient's esophagus in a minimally invasive outpatient procedure and it is “self-anchoring” and does not require invasive tissue fixation within the patient's GI tract, thereby reducing collateral tissue damage and minimizing its impact on the digestive process.

The invention relates to compositions and methods for the administration of therapeutic and/or diagnostic agents such as polypeptides to a mammal, and in particular, compositions suitable for oral administration. The invention provides polymeric particles, and in particular, nano/microparticles such as, but not limited to, microspheres and nanospheres, as well as methods of synthesizing them. The invention also provides methods of increasing the serum concentration of a therapeutic agent such as a polypeptide by orally administering polymeric particles comprising the therapeutic agent. The compositions of the invention allow the absorption of polypeptides through intestinal mucosa and intestinal cells and into the bloodstream of a mammal. The invention further provides a method of treating type II diabetes through the oral administration of compositions comprising insulin and also provides a related glucose-responsive insulin delivery system.

Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.

The present invention provides systems and methods for treating and controlling obesity and/or type II diabetes. In one aspect of the invention, an internal bypass device includes gastric and duodenal anchors coupled to each other and positioned on either side of the pylorus and a hollow sleeve designed to extend from the pylorus through at least a proximal portion of a patient's small intestine. The gastric and duodenal anchors are movable between collapsed configurations for advancement through the esophagus and an expanded configuration for inhibiting movement of the anchors through the pyloric sphincter. Thus, the bypass device can be placed and removed endoscopically through the patient's esophagus in a minimally invasive outpatient procedure and it is “self-anchoring” and does not require invasive tissue fixation within the patient's GI tract, thereby reducing collateral tissue damage and minimizing its impact on the digestive process.

The invention relates to the discovery that farnesoid X receptor (FXR) agonists can be used in combination with peroxisome proliferation activated receptor gamma (PPARγ) agonists to reduce drug-induced adverse side effects in patients suffering from conditions such as insulin resistance, Type II diabetes, metabolic syndrome, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and heart disease. Particularly, the present invention encompasses methods for treating patients suffering from drug-induced adverse side effects with selective PPARγ, dual PPARα/γ and pan PPARα/γ/δ agonists in combination with FXR agonists.

Aryl GPR119 agonists are provided. These compounds are useful for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control.

Oral pharmaceutical preparations of salts and polymorphs of a compound useful in the treatment of inflammatory and metabolic conditions and diseases are provided herein. The oral pharmaceutical preparation is useful for the treatment or prevention of conditions and disorders associated with energy homeostasis such as type II diabetes, lipid metabolism, adipocyte differentiation and inflammation.

Provided herein are compounds of the formula (1):

as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

The present invention provides methods of treating TNF-α-mediated disorders, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone or a pirfenidone analog and a second therapeutic agent that reduces TNF-α synthesis or that reduces TNF-α binding to a TNF receptor. The present invention further provides methods for treating non-alcoholic steatohepatitis, the method generally involving administering to an individual in need thereof an effective amount of pirfenidone. The present invention further provides methods of treating end-stage or advanced Type II diabetes, the methods generally involving administering to an individual in need thereof effective amounts of pirfenidone and insulin.